Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En avgjørende studie for å vurdere den kliniske nytten, ytelsen og sikkerheten til et fullstendig implanterbart cochleaimplantat (TICI)-system hos voksne (ELEVATE)

29. september 2026 oppdatert av: Cochlear

En avgjørende, pre-market, prospektiv, intervensjonsbasert, multikenterstudie for å evaluere klinisk nytte, ytelse og sikkerhet av TI1132-implantatet i en voksen populasjon med sensorineuritisk hørselshemning

This pivotal study examines the clinical efficacy and safety of an investigational totally implantable cochlear implant (TICI) system. The system includes a microphone placed under the skin to detect speech and sound from the environment, providing the option to hear without any visible external parts. This study will involve adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve (the nerve that carries sound signals from the ear to the brain). Participants will complete hearing tests and questionnaires to evaluate how well the system works and how it affects their daily life.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

56

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Colorado
      • Englewood, Colorado, Forente stater, 80113
        • Rocky Mountain Ear Center
    • Florida
      • Miami, Florida, Forente stater, 33136
        • University of Miami School of Medicine
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • University of Iowa
    • Michigan
      • Novi, Michigan, Forente stater, 48374
        • Michigan Ear Institute
    • Minnesota
      • Rochester, Minnesota, Forente stater, 55902
        • Mayo Foundation Rochester
    • Missouri
      • Kansas City, Missouri, Forente stater, 64111
        • Midwest Ear Institute
      • St Louis, Missouri, Forente stater, 63108
        • Washington University School of Medicine
    • New York
      • New York, New York, Forente stater, 10017
        • NYU Langone Health
    • Ohio
      • Beachwood, Ohio, Forente stater, 44122
        • University Hospitals Cleveland Medical Centre
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73120
        • Hearts for Hearing Foundation
    • Utah
      • Salt Lake City, Utah, Forente stater, 84132
        • University of Utah Hospitals and Clinics

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Individuals aged 18 years and older at time of consent.
  • Clinically established sensorineural hearing loss (SNHL) defined by a four frequency (500, 1000, 2000, 4000 Hz) pure-tone average unaided threshold (PTA4) of ≥70 dB HL in the ear to be implanted.
  • Compromised functional hearing in the aided condition defined as ≤40% correct on a word recognition test in the ear to be implanted.
  • Clinically established SNHL defined by a four-frequency (500, 1000, 2000 & 4000 Hz) pure-tone average unaided threshold (PTA4) of ≥30 dB HL in the contralateral ear.
  • Candidate is a fluent speaker in the language used to assess speech perception performance as determined by the investigator.
  • Direct access to a compatible Smart Phone.
  • Willing and able to provide written informed consent.

Exclusion Criteria:

  • Prior cochlear implantation, in either ear, or medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted.
  • Candidates with single-sided deafness as determined by the investigator.
  • Intra-axial (within-the-brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted.
  • Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment.
  • Presence of a tympanic membrane perforation or a history of otologic surgery within 3 months prior to enrolment, in the ear to be implanted.
  • Previously reported diagnosis of auditory neuropathy, in the ear to be implanted.
  • Ossification, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, in the ear to be implanted.
  • Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, skull fracture or CSF leaks.
  • Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the participant.
  • Severe, or poorer, sensorineural hearing loss for more than 20 years, as reported by the participant, in the ear to be implanted.
  • Medical or psychological conditions that contraindicate general anaesthesia, surgery, or participation in the clinical investigation as determined by the investigator.
  • Pre-existing skin condition that could jeopardize wound healing as judged by the investigator e.g., psoriasis, dermatitis, use of corticosteroids, uncontrolled diabetes.
  • Unrealistic expectations on the part of the participant, regarding the possible benefits, risks, and limitations inherent to the surgical procedure(s) and prosthetic devices, as determined by the Investigator.
  • Additional disabilities that may affect the participant's participation or safety during the clinical investigation.
  • Unable or unwilling to comply with all requirements of the clinical investigation, as determined by the investigator.
  • Pregnant or breastfeeding women.
  • Investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as spouse, parent, child or sibling.
  • Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of the investigation.
  • Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by Investigator or Sponsor to not impact this investigation).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Totally Implantable Cochlear Implant System

Participants will be implanted with the TI1132 implant

Totally Implantable Cochlear Implant System

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Speech recognition performance in quiet
Tidsramme: Preimplantation to 6-months post-activation

Percent correct scores in word recognition score from pre-implantation to post-implantation.

Preimplantation to 6-months post-activation
Incidence of adverse events and device deficiencies
Tidsramme: Implantation to 6- and 12-months post-activation

Frequency and severity of device and procedure-related adverse events, including device deficiencies.

Implantation to 6- and 12-months post-activation

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Speech, Spatial and Qualities of Hearing questionnaire (SSQ-12)
Tidsramme: Preimplantation to 6- and 12-months post-activation

Speech, Spatial, and Qualities of Hearing Scale global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability).

Preimplantation to 6- and 12-months post-activation
Speech recognition performance in noise
Tidsramme: Preimplantation to 6- and 12-months post-activation

Percent correct sentence score from preimplantation to 6- and 12-months post-activation.

Preimplantation to 6- and 12-months post-activation
Speech recognition performance in quiet
Tidsramme: Preimplantation to 12-months post-activation

Percent correct word recognition score in quiet from pre-implantation to post-implantation.

Preimplantation to 12-months post-activation
Cochlear Implant Quality of Life Profile (CIQOL-35)
Tidsramme: Preimplantation to 6- and 12-months post-activation

Cochlear implant hearing related quality of life score (CIQOL-35). Scored for six health domains (communication, emotional, entertainment, environment, listening effort, and social) each scaled from 0 to 100, where a higher score indicates better health.

Preimplantation to 6- and 12-months post-activation
Health Utilities Index (HUI 2/3)
Tidsramme: Preimplantation to 6- and 12-months post-activation

Health Utilities Index (HUI 2/3) global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health".

Preimplantation to 6- and 12-months post-activation
Living with Cochlear Implants Questionnaire (LivCI)
Tidsramme: Preimplantation to 6- and 12-months post-activation

Living with Cochlear Implants Questionnaire (LivCI) evaluates the impact of a hearing device on four domains, Participation (range 0 to 12), Psychosocial & Wellbeing (range 0 to 21), Stigma (range 0 to 15) and Management & Aesthetics (range 0 to 18), where a higher domain score indicates positive patient report.

Preimplantation to 6- and 12-months post-activation
Patient Satisfaction Survey
Tidsramme: From 6 to 12 months post-activation

Device satisfaction rating score. Scores range from 1 to 5, where a higher score indicates greater patient satisfaction with the TICI system.

From 6 to 12 months post-activation

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Craig Buchman, University of Utah

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

3. april 2026

Primær fullføring (Antatt)

1. oktober 2027

Studiet fullført (Antatt)

1. august 2028

Datoer for studieregistrering

Først innsendt

11. desember 2025

Først innsendt som oppfylte QC-kriteriene

11. desember 2025

Først lagt ut (Faktiske)

17. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere